Head of the State Service of Ukraine on Medicines and Drugs Control (SMDC) Roman Isaienko reported publicly on the outcomes of the SMDC’s activity in 2020

Опубліковано 24.02.2021 о 17:36

On 23 February 2020 the Head of the State Service of Ukraine on Medicines and Drugs Control reported publicly on the outcomes of the SMDC’s activity in 2020.

Members of the Public Council of the SMDC, representatives of NGOs, Mass Media, Heads of structural units of the SMDC and its regional authorities took part in the event.

Core points of the SMDC’s activity during 2020 were presented to the attention of the participants.

Roman Isaienko also informed that the quarantine restrictions influenced the process of performing duties by the SMDC’s employees. Most of work was done remotely with the help of modern information technologies. The SMDC jointly with the project of the international technical assistance updated the IT systems of the SMDC and developed the E-system of automation of processes, connected with issuance/reissuance of licenses for business entities in the field of manufacture, wholesale and retail trade and import of medicines.

The SMDC also developed important and timely amendments to the Order of the Ministry of Health of Ukraine as of 27.12.2012 № 1130 “On approval of the Procedure for confirmation of correspondence of conditions for medicines manufacture to the GMP requirements” New version of the Procedure covers confirmation of correspondence of conditions for medicines manufacture to the GMP requirements while remote assessment.

As a conclusion, the Head of the SMDC answered the experts’ questions.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Print button Версія для друку

Попередня

Scheduled meeting of the Public Council of the State Service of Ukraine on Medicines and Drugs Control was held on 23 February 2021

Наступна

Amendments to the Procedure for issuance of permissions for import or transition of narcotic drugs, psychotropic substances and precursors have been approved